Sinocare Inc

Sinocare Inc has a debt-to-equity ratio of 0.31, indicating a relatively conservative capital structure with a strong equity base. The company's current ratio of 1.39 suggests it has sufficient short-term assets to cover its short-term liabilities, though it is not significantly overcapitalized. However, the company's net cash position is negative after subtracting total debt, which raises liquidity concerns.

In terms of profitability, Sinocare Inc's return on equity (ROE) of 3.71% and return on assets (ROA) of 1.98% are below the typical thresholds for high-performing healthcare equipment firms. These metrics suggest the company is generating modest returns relative to its equity and asset base, which may indicate inefficiencies or a competitive disadvantage in its core operations.

The company's revenue is concentrated in a single business segment, as disclosed in its financial reporting, with no material geographic diversification beyond its primary market. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes, which could impact its revenue stability.

Sinocare Inc's growth trajectory appears to be modest, with no significant revenue acceleration in recent periods. The company's capital expenditures of -148.94 million CNY suggest a reduction in investment in new projects or infrastructure, which may signal a strategic shift or financial constraints. Analysts have assigned a mean recommendation of 1.25, indicating a generally positive outlook, but the absence of "buy" or "strong buy" ratings beyond a few suggests limited consensus on strong growth potential.

The company faces moderate liquidity risk due to its negative net cash position and a medium liquidity rating. While dilution risk is currently low, the absence of a significant difference between basic and diluted shares outstanding suggests no immediate threat from share issuance. However, the company's capital structure and cash flow dynamics should be closely monitored for any signs of financial stress.

Recent filings and transcripts do not indicate any major corporate events or strategic shifts. The company's focus remains on its core diagnostic testing and healthcare services, with no disclosed plans for major expansion or diversification. Analysts have provided a narrow range of price targets, suggesting a relatively stable but not highly optimistic outlook for the stock.

Sinocare's 18.5% revenue CAGR demonstrates strong top-line growth momentum over the four-year period ending in 2026.

Operating and net margins significantly exceed cohort medians, indicating superior profitability relative to peers in the medical equipment sector.

Analysts project 41.8% upside to a mean price target of 22.76, reflecting strong buy consensus among four analysts.

Cash conversion ratio of 1.95 ranks in the top quartile, suggesting efficient generation of cash from operations.

Return on equity of 3.71% outperforms the cohort median of 1.42%, highlighting better capital efficiency than most peers.

The company faces high credit risk, which could impair its ability to secure favorable financing terms in the future.

Capital expenditure intensity is in the bottom quartile of the cohort, potentially limiting future growth capacity or maintenance.

Revenue ¥1.21B, −4,4% YoY; Operating income −244,7% YoY.

• ▍Revenue ¥1.21B, −4,4% YoY
• ▍Operating income −244,7% YoY
• ▍Net income −266,8% YoY
• ▍Net margin -9.8%

Revenue ¥1.19B, +13,4% YoY; Operating income −124,0% YoY.

• ▍Revenue ¥1.19B, +13,4% YoY
• ▍Operating income −124,0% YoY
• ▍Net income −47,5% YoY
• ▍Net margin 2.6%

Revenue ¥1.22B, +9,2% YoY; Operating income −32,2% YoY.

• ▍Revenue ¥1.22B, +9,2% YoY
• ▍Operating income −32,2% YoY
• ▍Net income −6,9% YoY
• ▍Net margin 8.9%

Revenue ¥1.04B; Operating income ¥93.1M.

• ▍Revenue ¥1.04B
• ▍Operating income ¥93.1M
• ▍Net margin 6.9%

Revenue ¥4.66B, +4,9% YoY; Operating income −80,8% YoY.

• ▍Revenue ¥4.66B, +4,9% YoY
• ▍Operating income −80,8% YoY
• ▍Net income −71,6% YoY
• ▍Free cash flow −147,3% YoY
• ▍Net margin 2.0%

Revenue ¥4.44B, +9,5% YoY; Operating income +44,8% YoY.

• ▍Revenue ¥4.44B, +9,5% YoY
• ▍Operating income +44,8% YoY
• ▍Net income +14,7% YoY
• ▍Free cash flow +364,4% YoY
• ▍Net margin 7.3%

Revenue ¥4.06B, +2,7% YoY; Operating income −26,8% YoY.

• ▍Revenue ¥4.06B, +2,7% YoY
• ▍Operating income −26,8% YoY
• ▍Net income −36,3% YoY
• ▍Free cash flow −174,9% YoY
• ▍Net margin 7.0%

Revenue ¥3.95B, +67,4% YoY; Operating income +169,8% YoY.

• ▍Revenue ¥3.95B, +67,4% YoY
• ▍Operating income +169,8% YoY
• ▍Net income +315,1% YoY
• ▍Free cash flow +137,8% YoY
• ▍Net margin 11.3%

Revenue ¥2.36B; Operating income ¥139.3M.

• ▍Revenue ¥2.36B
• ▍Operating income ¥139.3M
• ▍Net margin 4.6%